Correlation between Carbapenem Consumption and Carbapenems Susceptibility Profiles of Acinetobacter baumannii and Pseudomonas aeruginosa in an Academic Medical Center in Thailand
Abstract
:1. Introduction
2. Results
2.1. Carbapenem Consumption
2.2. Microbiology and the Susceptibility Profiles of A. baumannii and P. aeruginosa
2.3. Relationship between Carbapenems Consumption and the Susceptibility Rate of A. baumannii to Imipenem and Meropenem and MDR-A. baumannii Data
2.4. Relationship between Carbapenem Consumption and the Susceptibility Rate of P. aeruginosa to Imipenem and Meropenem and MDR-P. aeruginosa Data
3. Discussion
4. Materials and Methods
4.1. Study Design and Data Collection
4.2. Statistical Analysis
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Pumart, P.; Phodha, T.; Thamlikitkul, V.; Riewpaiboon, A.; Prakongsai, P.; Limwattananon, S. Health and economic impacts of antimicrobial resistance in Thailand. J. Health Syst. Res. 2012, 6, 352–360. [Google Scholar]
- Christian, G.G.; Dominique, L.M.; Otto, C.; Yehuda, C. Clinical and Economic Impact of Common Multidrug-Resistant Gram-Negative Bacilli. Antimicrob. Agents Chemother. 2008, 52, 813–821. [Google Scholar]
- World Health Organization. Guidelines for the Prevention and Control of Carbapenem-Resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in Health Care Facilities; World Health Organization: Geneva, Switzerland, 2017; Available online: https://apps.who.int/iris/handle/10665/259462 (accessed on 11 November 2021).
- Molton, J.S.; Tambyah, P.A.; Ang, B.S.; Ling, M.L.; Fisher, D.A. The global spread of healthcare-associated multidrug-resistant bacteria: A perspective from Asia. Clin. Infect. Dis. 2013, 56, 1310–1318. [Google Scholar] [PubMed]
- Mendes, R.E.; Mendoza, M.; Banga Singh, K.K.; Castanheira, M.; Bell, J.M.; Turnidge, J.D.; Lin, S.S.; Jones, R.N. Regional resistance surveillance program results for 12 Asia-Pacific nations (2011). Antimicrob. Agents Chemother. 2013, 57, 5721–5726. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Suwantarat, N.; Carroll, K.C. Epidemiology and molecular characterization of multidrug-resistant Gram-negative bacteria in Southeast Asia. Antimicrob. Resist. Infect. Control 2016, 5, 15. [Google Scholar] [CrossRef] [Green Version]
- Kiratisin, P.; Chongthaleong, A.; Tan, T.Y.; Lagamayo, E.; Roberts, S.; Garcia, J.; Davies, T. Comparative in vitro activity of carbapenems against major Gram-negative pathogens: Results of Asia-Pacific surveillance from the COMPACT II study. Int. J. Antimicrob. Agents 2012, 39, 311–316. [Google Scholar] [CrossRef]
- Danchaivijitr, S.; Judaeng, T.; Sripalakij, S.; Naksawas, K.; Plipat, T. Prevalence of nosocomial infection in Thailand 2006. J. Med. Assoc. Thai. 2007, 90, 1524–1529. [Google Scholar]
- Werarak, P.; Waiwarawut, J.; Tharavichitkul, P.; Pothirat, C.; Rungruanghiranya, S.; Geater, S.L.; Chongthaleong, A.; Sittipunt, C.; Horsin, P.; Chalermskulrat, W.; et al. Acinetobacter baumannii nosocomial pneumonia in tertiary care hospitals in Thailand. J. Med. Assoc. Thai. 2012, 95, S23–S33. [Google Scholar] [PubMed]
- Dejsirilert, S.; Tiengrim, S.; Sawanpanyalert, P.; Aswapokee, N.; Malathum, K. Antimicrobial resistance of Acinetobacter baumannii: Six years of National Antimicrobial Resistance Surveillance Thailand (NARST) surveillance. J. Med. Assoc. Thai. 2009, 92, S34–S45. [Google Scholar]
- Hsu, L.Y.; Apisarnthanarak, A.; Khan, E.; Suwantarat, N.; Ghafur, A.; Tambyah, P.A. Carbapenem-Resistant Acinetobacter baumannii and Enterobacteriaceae in South and Southeast Asia. Clin. Microbiol. Rev. 2017, 30, 1–22. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Thirapanmethee, K.; Srisiri-a-nun, T.; Houngsaitong, J.; Montakantikul, P.; Khuntayaporn, P.; Chomnawang, M.T. Prevalence of OXA-Type β-Lactamase Genes among Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates in Thailand. Antibiotics 2020, 9, 864. [Google Scholar] [CrossRef] [PubMed]
- Paiboonvong, T.; Rodjun, V.; Houngsaitong, J.; Chomnawang, M.; Montakantikul, P.; Chulavatnatol, S. Comparative in vitro activity of sitafloxacin against multidrug-resistant and carbapenem-resistant Acinetobacter baumannii clinical isolates in Thailand. Pharm. Sci. Asia 2020, 47, 37–42. [Google Scholar] [CrossRef]
- Khuntayaporn, P.; Montakantikul, P.; Mootsikapun, P.; Thamlikitkul, V.; Chomnawang, M.T. Prevalence and genotypic relatedness of carbapenem resistance among multidrug-resistant P. aeruginosa in tertiary hospitals across Thailand. Ann. Clin. Microbiol. Antimicrob. 2012, 11, 25. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bell, B.G.; Schellevis, F.; Stobberingh, E.; Goossens, H.; Pringle, M. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect. Dis. 2014, 14, 13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Arepyeva, M.A.; Kolbin, A.S.; Sidorenko, S.V.; Lawson, R.; Kurylev, A.A.; Balykina, Y.E.; Mukhina, N.V.; Spiridonova, A.A. A mathematical model for predicting the development of bacterial resistance based on the relationship between the level of antimicrobial resistance and the volume of antibiotic consumption. J. Glob. Antimicrob. Resist. 2017, 8, 148–156. [Google Scholar] [CrossRef]
- Aremu, T.O.; Oluwole, O.E.; Adeyinka, K.O. An understanding of the drivers of infectious diseases in the modern world can aid early control of future pandemics. Pharmacy 2021, 9, 181. [Google Scholar] [CrossRef]
- Ayukekbong, J.A.; Ntemgwa, M.; Atabe, A.N. The threat of antimicrobial resistance in developing countries: Causes and control strategies. Antimicrob. Resist. Infect. Control 2017, 6, 47. [Google Scholar] [CrossRef]
- Papp-Wallace, K.M.; Endimiani, A.; Taracila, M.A.; Bonomo, R.A. Carbapenems: Past, present, and future. Antimicrob. Agents Chemother. 2011, 55, 4943–4960. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Codjoe, F.S.; Donkor, E.S. Carbapenem Resistance: A Review. Med. Sci. 2017, 6, 1. [Google Scholar] [CrossRef] [Green Version]
- Eichenberger, E.M.; Thaden, J.T. Epidemiology and Mechanisms of Resistance of Extensively Drug Resistant Gram-Negative Bacteria. Antibiotics 2019, 8, 37. [Google Scholar] [CrossRef] [Green Version]
- Zavascki, A.P.; Carvalhaes, C.G.; Picao, R.C.; Gales, A.C. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: Resistance mechanisms and implications for therapy. Expert Rev. Anti. Infect. Ther. 2010, 8, 71–93. [Google Scholar] [CrossRef] [PubMed]
- Mascarello, M.; Simonetti, O.; Knezevich, A. Correlation between antibiotic consumption and resistance of bloodstream bacteria in a University Hospital in North Eastern Italy, 2008–2014. Infection 2017, 45, 459–467. [Google Scholar] [CrossRef] [PubMed]
- Cao, J.; Song, W.; Gu, B.; Mei, Y.N.; Tang, J.P.; Meng, L.; Yang, C.Q.; Wang, H.; Zhou, H. Correlation between carbapenem consumption and antimicrobial resistance rates of Acinetobacter baumannii in a university-affiliated hospital in China. J. Clin. Pharmacol. 2013, 53, 96–102. [Google Scholar] [CrossRef] [PubMed]
- Tan, C.K.; Tang, H.J.; Lai, C.C.; Chen, Y.Y.; Chang, P.C.; Liu, W.L. Correlation between antibiotic consumption and carbapenem-resistant Acinetobacter baumannii causing health care associated infections at a hospital from 2005 to 2010. J. Microbiol. Immunol. Infect. 2015, 48, 540–544. [Google Scholar] [CrossRef] [Green Version]
- Yang, P.; Chen, Y.; Jiang, S.; Shen, P.; Lu, X.; Xiao, Y. Association between antibiotic consumption and the rate of carbapenem-resistant Gram-negative bacteria from China based on 153 tertiary hospitals data in 2014. Antimicrob. Resist. Infect. Control 2018, 7, 137. [Google Scholar] [CrossRef]
- Nicolau, D.P.; Carmeli, Y.; Crank, C.W.; Goff, D.A.; Graber, C.J.; Lima, A.L.; Goldstein, E.J. Carbapenem stewardship: Does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence. Int. J. Antimicrob. Agents 2012, 39, 11–15. [Google Scholar] [CrossRef]
- Abdallah, M.; Badawi, M.; Amirah, M.F.; Rasheed, A.; Mady, A.F.; Alodat, M.; Alharthy, A. Impact of carbapenem restriction on the antimicrobial susceptibility pattern of Pseudomonas aeruginosa isolates in the ICU. J. Antimicrob. Chemother. 2017, 72, 3187–3190. [Google Scholar] [CrossRef]
- Lee, C.M.; Lai, C.C.; Wang, Y.Y.; Lee, M.C.; Hsueh, P.R. Impact of susceptibility profiles of Gram-negative bacteria before and after the introduction of ertapenem at a medical center in northern Taiwan from 2004 to 2010. Diagn. Microbiol. Infect Dis. 2013, 75, 94–100. [Google Scholar] [CrossRef]
- Sousa, D.; Castelo-Corral, L.; Gutiérrez-Urbón, J.M.; Molina, F.; López-Calviño, B.; Bou, G.; Llinares, P. Impact of ertapenem use on Pseudomonas aeruginosa and Acinetobacter baumannii imipenem susceptibility rates: Collateral damage or positive effect on hospital ecology? J. Antimicrob. Chemother. 2013, 68, 1917–1925. [Google Scholar] [CrossRef] [Green Version]
- Yoon, Y.K.; Yang, K.S.; Lee, S.E.; Kim, H.J.; Sohn, J.W.; Kim, M.J. Effects of Group 1 versus Group 2 carbapenems on the susceptibility of Acinetobacter baumannii to carbapenems: A before and after intervention study of carbapenem-use stewardship. PLoS ONE 2014, 9, e99101. [Google Scholar] [CrossRef]
- Le Hello, S.; Falcot, V.; Lacassin, F.; Mikulski, M.; Baumann, F. Risk factors for carbapenem-resistant Acinetobacter baumannii infections at a tertiary care hospital in New Caledonia. Scand. J. Infect. Dis. 2010, 42, 821–826. [Google Scholar] [CrossRef] [PubMed]
- Sheng, W.H.; Liao, C.H.; Lauderdale, T.L.; Ko, W.C.; Chen, Y.S.; Liu, J.W.; Lau, Y.J.; Wang, L.H.; Liu, K.S.; Tsai, T.Y.; et al. A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii. Int. J. Infect. Dis. 2010, 14, e764–e769. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zheng, Y.L.; Wan, Y.F.; Zhou, L.Y.; Ye, M.L.; Liu, S.; Xu, C.Q.; He, Y.Q.; Chen, J.H. Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia. Am. J. Infect. Control 2013, 41, e59–e63. [Google Scholar] [CrossRef] [PubMed]
- Neves, M.T.d; Lorenzo, M.E.P.d; Almeida, R.A.M.B.; Fortaleza, C.M.C.B. Antimicrobial use and incidence of multidrug-resistant Pseudomonas aeruginosa in a teaching hospital: An ecological approach. Rev. Soc. Bras. Med. Trop. 2010, 43, 629–632. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- El Amin, N.; Giske, C.G.; Jalal, S.; Keijser, B.; Kronvall, G.; Wretlind, B. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: Alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates. APMIS 2005, 113, 187–196. [Google Scholar] [CrossRef] [PubMed]
Carbapenems Consumption (DDD/1000 Patient-Days) | |||||||
---|---|---|---|---|---|---|---|
Year | Meropenem | Imipenem | Doripenem | Ertapenem | Gr1 | Gr2 | Total |
2007 # | 23.23 | 12.42 | 0 | 1.75 | 1.75 | 35.65 | 37.40 |
2008 | 37.19 | 1.81 | 0.29 | 2.35 | 2.35 | 39.29 | 41.64 |
2009 | 25.36 | 1.59 | 5.44 | 3.86 | 3.86 | 32.39 | 36.25 |
2010 | 13.56 | 3.21 | 1.47 | 7.39 | 7.39 | 18.24 | 25.63 |
2011 | 20.28 | 3.9 | 0 | 13.57 | 13.57 | 24.18 | 37.75 |
2012 | 19.67 | 3.02 | 0 | 12.67 | 12.67 | 22.69 | 35.36 |
2013 | 15.27 | 3.73 | 0 | 17.36 | 17.36 | 19.00 | 36.36 |
r | −0.63 a | −0.44 b | −0.23 b | 0.97 a | 0.97 a | −0.84 a | −0.22 a |
p value | 0.129 | 0.319 | 0.620 | 0.000 ** | 0.000 ** | 0.018 * | 0.631 |
Isolates (n) | Wards | Antimicrobial Agents | Antimicrobials Susceptibility (%) by Year | Correlation | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | r | p | |||
Blood (154) | All wards (154) | Imipenem/cilastatin | 42.86 | 36.36 | 50.00 | 57.89 | 32.00 | 33.33 | 34.38 | −0.39 | 0.387 |
Meropenem | 42.86 | 36.36 | 52.38 | 57.89 | 32.00 | 33.33 | 30.00 | −0.46 | 0.294 | ||
MDR-AB | 57.14 | 61.54 | 42.31 | 42.86 | 72.00 | 72.73 | 63.64 | 0.44 | 0.318 | ||
Non-ICU wards (84) | Imipenem/cilastatin | 28.57 | 60.00 | 50.00 | 84.62 | 35.29 | 50.00 | 50.00 | 0.13 | 0.788 | |
Meropenem | 28.57 | 60.00 | 54.55 | 84.62 | 35.29 | 50.00 | 47.06 | 0.07 | 0.884 | ||
MDR-AB | 71.43 | 50.00 | 42.86 | 23.08 | 70.59 | 60.00 | 52.94 | −0.04 | 0.940 | ||
ICU wards (70) | Imipenem/cilastatin | 57.14 | 16.67 | 50.00 | 0.00 | 25.00 | 16.67 | 14.29 | −0.58 | 0.175 | |
Meropenem | 57.14 | 16.67 | 50.00 | 0.00 | 25.00 | 16.67 | 7.69 | −0.63 | 0.131 | ||
MDR-AB | 42.86 | 71.43 | 41.67 | 75.00 | 75.00 | 83.33 | 75.00 | 0.33 | 0.465 | ||
Sputum and BAL (1198) | All wards (1198) | Imipenem/cilastatin | 25.25 | 20.00 | 18.40 | 19.55 | 19.31 | 20.43 | 14.90 | −0.74 | 0.059 |
Meropenem | 24.49 | 20.69 | 18.01 | 19.55 | 17.59 | 19.46 | 13.56 | −0.83 * | 0.021 | ||
MDR-AB | 49.36 | 78.23 | 83.95 | 81.54 | 39.59 | 75.51 | 84.76 | 0.07 | 0.879 | ||
Non-ICU wards (694) | Imipenem/cilastatin | 24.53 | 22.22 | 23.30 | 21.62 | 20.61 | 19.19 | 15.18 | −0.92 ** | 0.003 | |
Meropenem | 25.00 | 23.33 | 22.33 | 21.62 | 18.60 | 18.18 | 13.68 | −0.97 ** | 0.000 | ||
MDR-AB | 46.07 | 75.82 | 80.39 | 81.69 | 83.33 | 76.19 | 86.36 | 0.07 | 0.879 | ||
ICU wards (504) | Imipenem/cilastatin | 26.09 | 16.36 | 10.00 | 16.95 | 16.90 | 21.84 | 14.58 | −0.25 | 0.589 | |
Meropenem | 23.91 | 16.36 | 10.34 | 16.95 | 15.71 | 20.93 | 13.41 | −0.29 | 0.528 | ||
MDR-AB | 53.73 | 82.14 | 90.00 | 81.36 | 84.51 | 74.73 | 83.00 | −0.25 | 0.589 |
Isolates (n) | Wards | Antimicrobial Agents | Antimicrobials Susceptibility (%) by Year | Correlation | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | r | p | |||
Blood (98) | All wards (98) | Imipenem/cilastatin | 100.00 | 83.33 | 53.85 | 77.78 | 61.54 | 58.33 | 78.57 | −0.50 | 0.250 |
Meropenem | 100.00 | 83.33 | 53.85 | 77.78 | 53.85 | 58.33 | 71.43 | −0.61 | 0.149 | ||
MDR-PA | 16.67 | 23.08 | 53.58 | 18.75 | 46.15 | 29.41 | 28.57 | 0.22 | 0.629 | ||
Non-ICU wards (72) | Imipenem/cilastatin | 100.00 | 88.89 | 54.55 | 75.00 | 63.64 | 77.78 | 50.00 | −0.70 | 0.083 | |
Meropenem | 100.00 | 88.89 | 54.55 | 75.00 | 63.64 | 77.78 | 50.00 | −0.70 | 0.083 | ||
MDR-PA | 22.22 | 10.00 | 54.55 | 21.43 | 50.00 | 16.67 | 50.00 | 0.38 | 0.398 | ||
ICU wards (26) | Imipenem/cilastatin | 100.00 | 66.67 | 50.00 | 100.00 | 50.00 | 0.00 | 100.00 | −0.28 | 0.549 | |
Meropenem | 100.00 | 66.67 | 50.00 | 100.00 | 0.00 | 0.00 | 85.71 | −0.39 | 0.383 | ||
MDR-PA | 0.00 | 66.67 | 50.00 | 0.00 | 33.33 | 60.00 | 12.50 | 0.02 | 0.965 | ||
Sputum and BAL (1288) | All wards (1288) | Imipenem/cilastatin | 65.81 | 87.17 | 74.58 | 80.84 | 67.25 | 61.39 | 70.44 | −0.39 | 0.394 |
Meropenem | 66.67 | 80.34 | 74.43 | 83.23 | 70.06 | 63.70 | 69.85 | −0.30 | 0.507 | ||
MDR-PA | 22.49 | 17.39 | 21.02 | 18.24 | 14.20 | 34.35 | 23.03 | 0.34 | 0.450 | ||
Non-ICU wards (930) | Imipenem/cilastatin | 72.00 | 86.21 | 75.37 | 81.48 | 67.18 | 62.34 | 73.79 | −0.49 | 0.270 | |
Meropenem | 72.00 | 78.16 | 76.69 | 83.70 | 69.77 | 62.34 | 76.14 | −0.28 | 0.548 | ||
MDR-PA | 17.86 | 20.00 | 19.55 | 19.69 | 12.30 | 33.62 | 18.49 | 0.07 | 0.879 | ||
ICU wards (358) | Imipenem/cilastatin | 54.76 | 90.00 | 72.09 | 78.13 | 67.50 | 61.05 | 64.29 | −0.22 | 0.630 | |
Meropenem | 57.14 | 86.67 | 67.44 | 81.25 | 71.05 | 63.16 | 58.33 | −0.27 | 0.553 | ||
MDR-PA | 31.58 | 10.00 | 23.26 | 12.50 | 20.00 | 36.08 | 32.20 | 0.39 | 0.391 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Paiboonvong, T.; Tedtaisong, P.; Montakantikul, P.; Gorsanan, S.; Tantisiriwat, W. Correlation between Carbapenem Consumption and Carbapenems Susceptibility Profiles of Acinetobacter baumannii and Pseudomonas aeruginosa in an Academic Medical Center in Thailand. Antibiotics 2022, 11, 143. https://doi.org/10.3390/antibiotics11020143
Paiboonvong T, Tedtaisong P, Montakantikul P, Gorsanan S, Tantisiriwat W. Correlation between Carbapenem Consumption and Carbapenems Susceptibility Profiles of Acinetobacter baumannii and Pseudomonas aeruginosa in an Academic Medical Center in Thailand. Antibiotics. 2022; 11(2):143. https://doi.org/10.3390/antibiotics11020143
Chicago/Turabian StylePaiboonvong, Taniya, Phatchareeporn Tedtaisong, Preecha Montakantikul, Sarun Gorsanan, and Woraphot Tantisiriwat. 2022. "Correlation between Carbapenem Consumption and Carbapenems Susceptibility Profiles of Acinetobacter baumannii and Pseudomonas aeruginosa in an Academic Medical Center in Thailand" Antibiotics 11, no. 2: 143. https://doi.org/10.3390/antibiotics11020143